AR030817A1 - Derivados de diazacicloalcanodiona - Google Patents

Derivados de diazacicloalcanodiona

Info

Publication number
AR030817A1
AR030817A1 ARP010104591A ARP010104591A AR030817A1 AR 030817 A1 AR030817 A1 AR 030817A1 AR P010104591 A ARP010104591 A AR P010104591A AR P010104591 A ARP010104591 A AR P010104591A AR 030817 A1 AR030817 A1 AR 030817A1
Authority
AR
Argentina
Prior art keywords
aryl
alkyl
lower alkyl
cycloalkyl
carboxy
Prior art date
Application number
ARP010104591A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR030817A1 publication Critical patent/AR030817A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de la formula (1), en donde R es carboxilo, carboxilo esterificado, o carboxilo amidado; R1 y R3 son independientemente alquilo inferior, (hidroxi, alcoxi inferior, amino, acilamino, mono- o di- alquilamino inferior, o mercapto)-alquilo inferior, alquilo inferior-(tio, sulfinil o sulfonil)-alquilo inferior, cicloalquilo, arilo, biarilo, (cicloalquil, aril, o biaril)- alquilo inferior, o (carboxi, carboxi esterificado, o carboxi amidado)-alquilo inferior; R2 es hidrogeno, alquilo inferior, cicloalquilo, arilo biarilo, arilaminocarbonilo, o aril- (oxi, tio, o amino); n es 1 o 2; Y es alquileno inferior o alquenileno inferior; y sales farmacéuticamente aceptables de los mismos; los cuales son utiles como antagonistas de LFA-1.
ARP010104591A 2000-10-02 2001-09-28 Derivados de diazacicloalcanodiona AR030817A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23723100P 2000-10-02 2000-10-02

Publications (1)

Publication Number Publication Date
AR030817A1 true AR030817A1 (es) 2003-09-03

Family

ID=22892870

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104591A AR030817A1 (es) 2000-10-02 2001-09-28 Derivados de diazacicloalcanodiona

Country Status (8)

Country Link
US (1) US6642225B2 (es)
EP (1) EP1326857A2 (es)
JP (1) JP4189216B2 (es)
AR (1) AR030817A1 (es)
AU (1) AU2002212301A1 (es)
CA (1) CA2424282A1 (es)
PE (1) PE20020420A1 (es)
WO (1) WO2002028842A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0301561D0 (en) * 2003-01-23 2003-02-26 Novartis Ag Organic compounds
TWI311557B (en) 2003-01-23 2009-07-01 Novartis A Pharmaceutically active diazepanes
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
JP2008507592A (ja) * 2004-06-09 2008-03-13 ジェネンテック・インコーポレーテッド 環状肉芽腫又はサルコイドの治療法
DK2444079T3 (en) * 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
US8926990B2 (en) * 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
CA2635354C (en) * 2005-12-29 2012-07-10 Immupharma France Sa Compositions and methods for the inhibition of phospholipase a2
CA2635359A1 (en) * 2005-12-29 2007-07-05 Immupharma France Sa Compositions and methods for synthesizing heterocyclic therapeutic compounds
US20080033167A1 (en) 2005-12-29 2008-02-07 Gilles Guichard Compositions and methods for synthesizing heterocyclic therapeutic compounds
US20090155176A1 (en) 2007-10-19 2009-06-18 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
WO2009128933A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Aerosolized lfa-1 antagonists for use in localized treatment of immune related disorders
US20090258070A1 (en) * 2008-04-15 2009-10-15 John Burnier Topical LFA-1 antagonists for use in localized treatment of immune related disorders
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc RELEASE OF LFA-1 ANTAGONISTS AGAINST THE GAS-DARM SYSTEM
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
KR102157608B1 (ko) 2012-07-25 2020-09-18 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008186A1 (en) * 1978-08-08 1980-02-20 Beecham Group Plc Cyclic diamides, a process for their preparation and their pharmaceutical compositions
IL92011A0 (en) 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
WO1992007568A1 (en) 1990-11-01 1992-05-14 Smithkline Beecham Corporation η-TURN PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS
HUT68769A (en) 1991-05-07 1995-07-28 Merck & Co Inc FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE
ATE174913T1 (de) 1992-07-31 1999-01-15 Bristol Myers Squibb Co Diphenyl oxazole-, thiazole- und imidazole- derivate als inhibitoren der wiederaufnahme des adenosins
US5990112A (en) 1996-06-18 1999-11-23 Affymax Technologies N.V. Inhibitors of metalloproteases pharmaceutical compositions comprising same and methods of their use
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
CN1127488C (zh) 1996-04-24 2003-11-12 诺沃挪第克公司 具有生长激素释放特性的化合物
EP0914319B1 (en) * 1996-05-20 2001-11-21 Teijin Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
US5932579A (en) 1996-06-18 1999-08-03 Affymax Technologies N.V. Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use
WO1998009987A1 (en) 1996-09-06 1998-03-12 Biochem Pharma, Inc. Lactam inhibitors of thrombin
NZ500353A (en) 1997-04-14 2002-02-01 Cor Therapeutics Inc Cyclic diaza compounds that are selective inhibitors of factor Xa
US6369063B1 (en) 1997-04-14 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
AU747531B2 (en) 1997-04-14 2002-05-16 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
TR200103427T2 (tr) * 1999-05-07 2002-10-21 Texas Biotechnology Corporation Integrinlerin reseptörlerine bağlanmasını engelleyen propanoik asit türevleri.
US6399599B1 (en) 1999-10-13 2002-06-04 Novartis Ag Substituted 2-oxo-1,4-diazacycloalkanes
ECSP003707A (es) 1999-10-13 2002-05-23 Novartis Ag Diazepanes

Also Published As

Publication number Publication date
US20020061878A1 (en) 2002-05-23
JP2004510768A (ja) 2004-04-08
WO2002028842A3 (en) 2002-06-13
EP1326857A2 (en) 2003-07-16
PE20020420A1 (es) 2002-06-27
AU2002212301A1 (en) 2002-04-15
CA2424282A1 (en) 2002-04-11
JP4189216B2 (ja) 2008-12-03
US6642225B2 (en) 2003-11-04
WO2002028842A2 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
AR030817A1 (es) Derivados de diazacicloalcanodiona
ES2196396T3 (es) Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
NL300877I2 (nl) obeticholzuur
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
TR200100438T2 (tr) Hepatit C inhibitörü peptitler
CY1110104T1 (el) Παραγωγα της πιπεραζινης ως αναστολεις ταχυκινινων
EP1477482A4 (en) NEW PHENYLALANINE DERIVATIVE
AU7874001A (en) Novel phenylalanine derivatives
DE60225719D1 (de) Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren
DE60317208D1 (de) Pleuromutilinderivate als antimikrobielle mittel
ZA200309887B (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
CY1107509T1 (el) Αμινοθειαζολες ως αναστολεις κυκλινη - εξαρτωμενων κινασεων
ATE222894T1 (de) Substituierte aminophenylisoxazolinderivate verwendbar als antimikrobielle agenzien
DE69716925D1 (de) Isoxazoline derivate und ihre verwendung als antimikroben
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
DE69717970D1 (de) Chinolin carbonsaure-derivate und ihre salze
TR200002605T2 (tr) Nitrik oksit sentaz inhibitörleri olarak faydalı halojene amidino amino asit türevleri
HUP0202876A2 (hu) Karboxipeptidáz U gátló új vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK1362844T3 (da) Benzylaminanalog
DE60036558D1 (de) Phthalazinon-derivate als pde 4 hemmer
CO4761036A1 (es) Mezclas fungicidas
TR200103685T2 (tr) Optik olarak aktif pirrolopiridazin türevleri
MX2007005892A (es) Derivados de acido piridonacarboxilico novedosos y sales de los mismos.
BR0313400A (pt) N-aril-2-oxazolidinonas e seus derivados
AR006754A1 (es) Derivados de quinoxalina utiles en terapia

Legal Events

Date Code Title Description
FB Suspension of granting procedure